Daily Stock Analysis, CANF, Can Fite Biopharma Ltd, priceseries

Can Fite Biopharma Ltd. Daily Stock Analysis
Stock Information
Open
2.90
Close
2.62
High
2.90
Low
2.60
Previous Close
2.93
Daily Price Gain
-0.31
YTD High
24.30
YTD High Date
Mar 20, 2019
YTD Low
2.14
YTD Low Date
Aug 23, 2019
YTD Price Change
-16.58
YTD Gain
-86.35%
52 Week High
25.95
52 Week High Date
Nov 21, 2018
52 Week Low
2.14
52 Week Low Date
Aug 23, 2019
52 Week Price Change
-16.88
52 Week Gain
-86.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2018
23.40
Jan 18. 2018
26.42
8 Trading Days
12.89%
Link
LONG
Jan 22. 2018
27.15
Feb 1. 2018
32.10
8 Trading Days
18.25%
Link
Company Information
Stock Symbol
CANF
Exchange
NYSE MKT
Company URL
http://http://www.canfite.co.il
Company Phone
-
CEO
N/A
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases, as well as sexual dysfunction.

Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases, as well as sexual dysfunction. It offers CF101, which has completed Phase II/III clinical trials for the treatment of psoriasis; completed Phase II clinical trials for the treatment of rheumatoid arthritis; completed Phase I clinical study for the treatment of osteoarthritis; and completed Phase I study for the treatment of uveitis, as well as is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension. The company also develops CF102 that conducts a Phase II study for treating hepatocellular carcinoma and hepatitis C virus; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.